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Abstract
Annually, ovarian cancer (OC) affects 240,000 women worldwide and is the
most lethal gynecological malignancy. High-grade serous OC (HGSOC) is the
most common and aggressive OC subtype, characterized by widespread genome
changes and chromosomal instability and is consequently poorly responsive to
chemotherapy treatment. The objective of this study was to investigate the role
of the microRNA miR-433 in the cellular response of OC cells to paclitaxel
treatment. We show that stable miR-433 expression in A2780 OC cells results
in the induction of cellular senescence demonstrated by morphological changes,
downregulation of phosphorylated retinoblastoma (p-Rb), and an increase in b-
galactosidase activity. Furthermore, in silico analysis identified four possible
miR-433 target genes associated with cellular senescence: cyclin-dependent
kinase 6 (CDK6), MAPK14, E2F3, and CDKN2A. Mechanistically, we demon-
strate that downregulation of p-Rb is attributable to a miR-433-dependent
downregulation of CDK6, establishing it as a novel miR-433 associated gene.
Interestingly, we show that high miR-433 expressing cells release miR-433 into
the growth media via exosomes which in turn can induce a senescence bystan-
der effect. Furthermore, in relation to a chemotherapeutic response, quantita-
tive real-time polymerase chain reaction (qRT-PCR) analysis revealed that only
PEO1 and PEO4 OC cells with the highest miR-433 expression survive paclit-
axel treatment. Our data highlight how the aberrant expression of miR-433 can
adversely affect intracellular signaling to mediate chemoresistance in OC cells
by driving cellular senescence.
ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,





Worldwide ovarian cancer affects over 240,000 women
annually. The most common subtype among ovarian can-
cer malignancies is high-grade serous ovarian cancer
(HGSOC) which accounts for ~70% of all ovarian cancer
presentations [1]. On average, the 5-year survival rate for
HGSOC ranges from 20% to 40% and is primarily depen-
dent on the initial stage of diagnosis [2]. The standard
management of ovarian cancer includes cytoreductive sur-
gery followed by adjuvant chemotherapy consisting of a
DNA-binding platinum agent (carboplatin) and a microtu-
bule-stabilizing agent (paclitaxel). Despite the often initial
favorable response, patients unfortunately usually relapse
within 6–12 months [3]. The rational given for such a high
recurrence rate is predominantly associated with the
“repopulation hypothesis” which assumes that recurrence
depends on the ability of cancer cells to survive chemother-
apy due to an intrinsic or acquired resistance [2]. Resis-
tance to the microtubule-stabilizing agent, paclitaxel, can
be associated with multiple mechanisms including an
increased efflux of the drug, aberrant paclitaxel binding [4]
or a disruption of the spindle assembly checkpoint (SAC)
function [5]. Importantly, molecular pathways targeted by
paclitaxel and carboplatin chemotherapies, determine their
best efficacy toward actively dividing cells [4]. Thus, cell
cycle arrest and subsequent cellular apoptosis is the pre-
dominant mechanism of action of these chemotherapies.
Cellular senescence is a state of cell cycle arrest initiated
by various stimuli such as telomere shortening, stress fac-
tors (oncogenes), or chemical moieties (e.g., chemothera-
pies) [6]. Due to the growth repression feature, cellular
senescence is widely regarded as a tumor suppressor mech-
anism [7]. This view, however, has recently been chal-
lenged, whereby it is widely believed that cellular
senescence induction can contribute to the development
and further progression of cancer cells [8]. Senescent cells
demonstrate various characteristic features including
changes in morphology and molecular signaling. The initia-
tion and maintenance of senescence is mediated by the
p53/p21 and p16/Retinoblastoma (Rb) pathways [8]. An
increase in the p16 and p21 cyclin-dependent kinase inhibi-
tors negatively regulates Cyclin/cyclin-dependent kinase
(CDK) complexes and prevents the phosphorylation of Rb
[9]. Therefore, hypophosphorylated Rb is a hallmark of cell
cycle arrest. Dysregulation in these two molecular pathways
is a feature of many cancers including ovarian tumors [10].
For the last decade, extensive research has identified a
pivotal role of microRNAs in cancer [11]. We have previ-
ously published that high expression of miR-433 is signifi-
cantly associated with poor progression-free survival (PFS)
in patients with HGSOC and demonstrated that downregu-
lation of the mitotic arrest deficiency protein MAD2 (also
known as MAD2L1) by miR-433 induced cellular chemore-
sistance to paclitaxel [5]. Shih et al., 2011 also demon-
strated an association between miR-433 and poorer survival
in ovarian cancer, while others have demonstrated altered
miR-433 expression in gastric cancer [12], myeloprolifera-
tive neoplasms [13] and lung dysplasia [14]. Additionally,
many of the published miR-433 protein targets are strongly
associated with cancer including GRB2, SFRP2, CREB1,
and HDAC6 [15–19]. Moreover, miR-433 expression is
correlated with the inhibition of cell migration, prolifera-
tion, and differentiation [13, 17, 20]. To date, however, the
mechanism by which miR-433 expression promotes resis-
tance to paclitaxel treatment in cancer cells is not known.
Here, we examined the underlying mechanism of miR-
433-mediated chemoresistance to the chemotherapeutic
paclitaxel in ovarian cancer. We demonstrate that
increased resistance to paclitaxel in miR-433 overexpress-
ing ovarian cancer cell lines is not only mediated through
the inhibition of apoptosis [5] but also through miR-433-
induced cellular senescence. Moreover, we present novel
data showing the downregulation of CDK6 by miR-433 as
a putative mediator of miR-433-induced senescence.
Additionally, we demonstrate that growth-conditioned
media (GCM) from miR-433 expressing cells have the
potential to modulate the tumor microenvironment by
inducing growth inhibition and cellular senescence in
neighboring cells. Our data highlight how the aberrant
expression of miR-433 and the miR-433 protein targets
can adversely affect intracellular signaling activities to
mediate chemoresistance in ovarian cancer cells.
Materials and Methods
Tissue culture
A2780, PEO1, and PEO4 cells were obtained from the
European Collection of Cell Cultures (ECACC) and cul-
tured in RPMI (Roswell Park Memorial Institute medium).
However this name is not used in the scientific literature.
1640 medium supplemented with 10% v/v FCS (fetal calf
serum) and 0.3 mg/mL glutamine. The miR-433 stable cell
lines were cultured in RPMI 1640 medium supplemented
with 10% v/v FCS, 0.3 mg/mL glutamine, and puromycin
(4 lg/mL) as a selection antibiotic. All cells were main-
tained at 37°C with 5% CO2 and were routinely tested and
proven negative for mycoplasma contamination.
Generation of the A2780 ovarian cancer cell
line with ectopic expression of hsa-miR-433
A2780 cells stably expressing hsa-miR-433 were constructed
using commercially available plasmids (shMIMIC Lentiviral
Human microRNA nonsilencing control and miRIDIAN
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microRNA hsa-miR-433 shMIMIC), both harboring a Tur-
boGFP reporter (HMR5872 and VSH5841-202526908,
respectively, Thermo Fisher Scientific Inc., Waltham, MA,
USA) and used according to the manufacturer’s protocol.
Stable selection of transfectants was ensured by a puromy-
cin (4 lg/mL) selection process to generate a miR-433 or
miR-control expressing cell lines. Successful transduction
was assessed by positive tGFP expression, microRNA
expression, and target gene downregulation.
SDS-PAGE and Western blotting
Sodiumdodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting were performed as
described previously [5]. The following antibodies were
used: MAD2 (BD BioScience, San Jose, CA, USA), HDAC6
(Millipore, Billerica, MA, USA), Caspase 3, p21, poly (ADP-
ribose) polymerase (PARP), CDK6 and p-Rb (Ser 807/811)
(Cell Signalling, Danvers, MA, USA), b-actin and p16
(Santa Cruz Biotechnology, Dallas, Texas, USA), beta (b)-
galactosidase (Abcam, Cambridge, UK).
Cell viability assay
Ovarian cancer cells stably expressing miRIDIAN hsa-miR-
433 or control shMIMIC were treated with (10, 25,
50 nmol/L) paclitaxel (Sigma, St. Louis, MO, USA) for 24 h
and analyzed by the MTT assay, as previously described.
Colony formation assay
Stable miR-control and miR-433 expressing cells were
seeded onto six-well plates at a density of 1500 cells per well
as previously described [21]. Resultant colonies were fixed
with 4% paraphormaldehyde (Electron Microscopy Sci-
ence, Hatfield, PA, USA), stained with crystal violet (10%
v/v—Sigma) then counted and the % colony formation was
calculated using control untreated cells as a calibrator.
b-galactosidase staining
Stable miR-control and miR-433 A2780 expressing cells
were seeded onto six-well plates at a density of
3 9 105 cells per well and allowed to grow for 48 h. The
cells were then fixed and stained using a senescence
b-galactosidase staining kit (Cell Signalling) according to
the manufacturer’s instructions.
Quantitative real-time PCR
For the analysis of miR-433 expression in miR-433 stable
cell lines, total RNA was isolated from the cell pellets
using the TRIzol Reagent (Invitrogen, Life Technologies,
Grand Island, NY, USA) based on the manufacturer’s
protocol. RNA (50 ng) was reverse transcribed using the
TaqMan MicroRNA reverse transcription kit (Applied
Biosystems). Quantitative real-time polymerase chain
reaction (qRT-PCR) was performed using TaqMan
chemistry (Applied Biosystems) on 9700 Thermocycler
(Applied Biosystems) to analyze the expression of each
microRNA by the comparative delta Ct method normal-
ized using RNU6B as endogenous control.
For the analysis of miR-433 expression in ovarian cancer
cell lines, total RNA was isolated from cultured cells using
the mirVanaTM miRNA Isolation Kit (Ambion, Grand Island,
NY, USA) according to the manufacturer’s instructions.
RNA (1 lg) was reverse transcribed using the miScript II RT
Kit (Qiagen). qRT-PCR was performed using SYBR-based
chemistry (Qiagen, Germantown, MD, USA) on the Light-
cycler 480 system (Roche, Clare, Ireland) to analyze the
expression of each microRNA by the comparative delta Ct
method normalized using RNU6B as endogenous control.
Transient transfection
Cells were transiently transfected with 100 nmol/L of pre-
miR-433, scrambled control miRNA, anti-miR-433, or
anti-miR-control (Dharmacon, Lafayette, CO, USA) using
TransIT-X2 (Mirrus, Madison, WI, USA) transfecting
reagent according to the manufacturer’s protocol.
Coculture with growth condition media
GCM was obtained from ~80% confluent A2780, PEO1,
and PEO4 cells or miR-control-stable and miR-433-stable
A2780 cells. Next, GCM was centrifuged at 1259g for
5 min and filtered to remove debris and dead cells and
added to recipient A2780 or miR-433-stable cells, respec-
tively. This procedure replacing fresh GCM was repeated
every 24 h for 96 h. Following this treatment, Western
blot analysis or MTT viability assay was performed.
MicroRNA target prediction
Target genes of individual miRNAs were calculated using
seven different databases: DIANA-microT [22], miRDB
[23] and TargetScan [24], miRANDA, PITA [25], RNA22,
and miRWalk [26]. The results for DIANA-microT, miR-
DB, and TargetScan were updated to include the latest
versions of these databases. Genes were assigned a value
of 1 per algorithm where a positive prediction was made.
These values were summed and only genes with a score
of 5 or higher (positive prediction by five of seven data-
bases) were included in further analysis.
Protein–Protein Interaction (PPI) networks were gen-
erated within Cytoscape (version 3.01) [27]. All interac-
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tion data were obtained from STRING ver 9.05 using
the data import function through CluePedia ver 1.07.
Only experimentally validated and curated interactions
were used to build PPI networks. Gene Ontology (GO)
function enrichment for downstream target genes was
performed in Cytoscape using the (ClueGo app (version
2.07), Cordeliers Research Center, Paris, France) [28].
Statistical analysis
All data are presented as the mean  SEM for at least
three independent experiments. For each experiment, the
statistical tests are indicated in the results section. Stu-
dent’s t-test was conducted using Prism 5 (Graphpad
Software, La Jolla, CA, USA) to compare the means.
Results
Stable expression of miR-433 in A2780 cells
attenuates cellular apoptosis and results in
a distinct morphological change
We previously demonstrated that transient overexpression
of pre-miR-433 in A2780 cells decreased the apoptotic
response of ovarian cancer cells to paclitaxel treatment
[5]. Here, we have investigated the long-term effects of
miR-433 overexpression in ovarian cancer cells. To
address this, a miR-433 overexpressing A2780 cell line
and a matched miR-control (miR-433 negative) were gen-
erated. To ensure that only transduced cells were further
cultured, puromycin selection was applied to the stable
transfectants. Cells were also routinely monitored for the
retention of GFP as a positive control of miR-433 or
miR-control expression.
miR-433 expression was confirmed by qRT-PCR analy-
sis and was significantly upregulated in the stably trans-
fected cells compared to control (P < 0.001) (Fig. 1A).
To confirm that stable overexpressed miR-433 was func-
tionally active, we examined the protein expression of
two known miR-433 target genes, MAD2 [5] and HDAC6
[15]. The levels of both proteins were downregulated in
the miR-433 overexpressing cells when compared to con-
trols (Fig. 1B).
Previously, we have reported that transient transfection
of miR-433 rendered A2780 cells more resistant to paclit-
axel treatment [5]. Here, we investigated if stable miR-
433 expression would also enhance paclitaxel resistance.
Transduced A2780 cells were subjected to a range of pac-
litaxel concentrations. At 25 and 50 nmol/L, miR-433
expressing cells demonstrated greater cell viability com-
pared to controls (P < 0.05) (Fig. 1C). Furthermore,
Western blot analysis demonstrated diminished PARP
cleavage in the stable miR-433 expressing cells, suggesting
a miR-433-dependent reduction in apoptosis (Fig. 1D).
Therefore, a similar apoptotic response is obtained irre-
spective of whether miR-433 is expressed transiently [5]
or stably.
Following 1 week of functional miR-control/miR-433
expression evidenced by GFP fluorescence, we observed a
significant morphological difference between the miR-
433-stable and the miR-control-stable cells (Fig. 1E). Spe-
cifically, miR-433-stable cells appeared more flattened,
enlarged and enriched with cytoplasmic granules com-
pared to control cells (Fig. 1E). Additionally, miR-433
stable cells formed significantly less colonies compared to
miR-controls (Fig. 1F). Taken together these results dem-
onstrate that miR-433 induced both phenotypic and mor-
phological changes in cancer cells. Importantly, the
morphological changes were not apparent in cells tran-
siently transfected with miR-433 [5].
Bioinformatic identification of putative
miR-433 target genes identifies potential
links to cellular senescence
The resistance to paclitaxel and changes in growth and
morphological characteristics suggested that over expres-
sion of miR-433 was inducing cellular senescence in the
stable transfected A2780 cells. To explore this hypothe-
sis further, we first set out to identify additional puta-
tive targets of miR-433 using a bioinformatic approach.
To identify candidate miR-433 targets, we utilized seven
different prediction algorithms (TargetScan, DIANA
Micro-T, miRWalk, RNA22, miRANDA, PITA, and
miRDb). From this analysis, we identified possible 6224
candidate genes. However, applying the principle that a
candidate gene must be detected by five out of seven
algorithms, this list was reduced to 1204 genes (Table
S1). In this analysis, both MAD2 (also known as
MAD2L1) and HDAC6 were identified as targets by
seven and five algorithms respectively, thus, giving cred-
ibility in the candidate gene selection criteria.
Having identified candidate miR-433 target genes, we
next wanted to determine the potential for these genes
to impact on cellular senescence. Well-established genes
associated with cellular senescence were identified from
the literature, yielding a list of approximately 86 genes
(Table S3). Next, we constructed an overlap with the
1204 putative miR-433 target genes and identified four
overlapping genes including CDK6, MAPK14, E2F3, and
CDKN2A (Fig. 2A). To further investigate the interac-
tion between potential miR-433 targets and senescence-
associated genes, we built an interaction network in
Cytoscape using both ClueGo and Cluepedia apps. Only
previously experimentally validated PPIs were
included in the construction of the network. From this
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analysis, we identify a significant number of interactions
between well-established cellular senescence genes and
our list of miR-433 target genes (Fig. 2B). By focusing
in on the first degree neighbors of the four overlapping
genes we identified a number of possible miR-433 tar-
gets which regulate the function of key cellular senes-
cence genes such as Rb (Fig. 2C). Overall, this
indicated the possible role of miR-433 regulating the







Figure 1. Stable expression of miR-433 in A2780 cells attenuates cellular apoptosis and results in a distinct morphological and proliferative
change. (A) Quantitative real-time PCR (qRT-PCR) values for miR-433 in the miR-433-stable A2780 cells compared to miR-433-stable cells showing
a significant (P < 0.05) fold increase in miR-433 levels. (B) Western blot analysis showing downregulation of two miR-433 targets, MAD2 and
HDAC6 in the A2780 miR-433-stable expressing cell line. (C) Histogram representation of the response of the stable miR-433 versus control-miR
cell lines post 24 h paclitaxel (10, 25, 50 nmol/L) treatment. Student’s t-test was used for the comparison of means and demonstrates an
increased resistance of the miR-433-stable cell line compared to controls at 25 and 50 nmol/L paclitaxel (P < 0.05). (D) Western blot analysis of
poly (ADP-ribose) polymerase (PARP) cleavage in the miR-433-stable and miR-control-stable cell line treated with 50 nmol/L paclitaxel for 24 h
demonstrating a decreased PARP cleavage in the miR-433-stable expressing A2780 cells. (E) Increased miR-433 expression influences the cellular
morphology of A2780 cells appreciated by green fluorescent protein (GFP) expression with a resultant flattened and enlarged cellular morphology.
Magnification 209. (F) Colony forming assay of miR-control and miR-433 stable tranfected A2780 cells stained with crystal violet (magnification
49) demonstrating a significantly lower colony formation ability in the miR-433 stable transfectants. Error bars represent SEM. *P < 0.05,
***P < 0.001.
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Stable expression of miR-433 induces
cellular senescence
Following the in silico analysis of miR-433 targets, we
investigated two key molecular pathways involved in the
initiation and maintenance of cellular senescence namely,
p53/p21 and p16/Rb [8]. Firstly, to investigate if miR-433
overexpression could induce senescence the protein levels
of p16, phosphorylated Rb (p-Rb), and p21 were anaylzed
in the miR-433-stable A2780 cells. This analysis showed
that p-Rb was decreased in A2780 cells stably transfected
with miR-433. Notably, there was no reciprocal upregula-
tion of p16 and p21 in these cells (Fig. 3A). The senes-
cence-associated b-galactosidase activity in these cells was
determined by Western blot and b-galactosidase staining
analyses and revealed a significant upregulation of senes-
cence-associated b-galactosidase activity in miR-433-stable
cells compared to controls (P < 0.0001) (Fig. 3B and C).
To further explore the relationship between miR-
433 expression and p-Rb, we profiled native miR-433
expression by qRT-PCR in the parent A2780 cells and
two other epithelial ovarian cancer (EOC) lines, PEO1
and PEO4. PEO1 is cisplatin sensitive, while PEO4 is cis-
platin resistant, derived from the same patient before and
after the development of recurrent drug-resistant tumor
[29]. Here, we show that the cisplatin-resistant PEO4 cells
displayed significantly higher levels of miR-433 compared
to the A2780 (P = 0.0012) and PE01 cells (P = 0.0028)
(Fig. 3D). Additionally, when we analyzed the protein
expression of p-Rb there was a demonstrable decrease in
expression of p-Rb in the PEO1 and PEO4 compared to
the A2780 cells with the cisplatin-resistant PEO4 line
demonstrating the largest decrease in p-Rb expression
across the three cell lines (Fig. 3E). Of note, similar to
our miR-433-stable cell line, the status of p-Rb in EOC
cells was also independent of p21 or p16 expression
(Fig. 3A and E, respectively).
Senescent cells are known to contribute to the tumor
microenvironment by secreting proinflammatory cyto-
kines known as the senescence-associated secretory phe-
A B
C
Figure 2. Bioinformatic analysis highlights miR-433 potential influence on cellular senescence. (A) Venn diagram showing overlapping genes
(CDK6, MAPK14, CDKN2B, and E2F3) between senescence-associated genes and miR-433 target genes. (B) Overview of the interaction between
miR-433 target genes (blue nodes) and senescence-associated genes (blue nodes), overlapping nodes are colored yellow. (C) Focus on overlapping
genes (yellow nodes) and first degree neighbors in both the senescence-associated genes (green nodes) or predicted miR-433 targets (blue
nodes). Blue edges indicate experimentally validated protein–protein interactions, magenta edges indicate predicted interactions with miR-433 (red
node).
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notype (SASP). To investigate this further, we measured
the levels of interleukin-6 (IL-6) and interleukin-8 (IL-8)
(two key cytokines associated with SASP) in the A2780,
PEO1, and PEO4 cells using V-PLEX Human Proinflam-
matory (Meso Scale Discovery) kit (Fig. 3F and G). Inter-
estingly, the levels of IL-6 were significantly higher in the
PEO1 and PEO4 cells compared to the A2780 cells (~80-
fold, P < 0.01 and ~380-fold, P = 0.01, respectively)
(Fig. 3F) mirroring the increased levels of miR-433 in
PEO1 and PEO4 compared to the A2780 cells (Fig. 3D).
Similarly, IL-8 levels were significantly higher in PEO1







Figure 3. miR-433 stable expression induces cellular senescence. (A) Western blot analysis for p-Rb, p21, and p16 in miR-433-stable and miR-
control-stable cell lines showing downregulation of p-RB with no demonstrable upregulation of p16 and p21. (B) Western blot analysis for b-
galactosidase activity in miR-433-stable and miR-control-stable cell lines demonstrating an increase in b-galactosidase activity in miR-433 cells. (C)
Senescence-dependent b-galactosidase activity staining in the miR-433-stable and miR-control-stable cell lines showing significant upregulation of
positively stained cells in miR-433 cell line. (D) qRT-PCR determination of the baseline levels of miR-433 in the A2780, PEO1, and PEO4 ovarian
cancer cell lines. (E) Western blot analysis of the baseline levels of expression of p-Rb, p21, and p16 in the A2780, PEO1, and PEO4 ovarian
cancer cell lines showing a demonstrable decrease in p-Rb expression in the PEO1 and PEO4 paired cell line independent of p21 and p16
compared to A2780 cells. Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001. (F and G) Analysis of cytokine secretion of interleukin-
6 (IL-6), and interleukin-8 (IL-8) in the growth media of A2780, PEO1, and PEO4 cells, showing significant increases in IL-6 in PEO1 and PEO4 cells
and IL-8 in PEO1 cells when compared to miR-433 negative A2780 cells. Error bars represent SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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although not reaching significance on IL-8 levels were on
average ~380-fold increased in PEO4 cells when compared
with A2780 cells (P = 0.09) (Fig. 3G).
miR-433 regulates the expression of CDK6
As the data demonstrated that the miR-433-stable-cell-
induced morphological changes (Fig. 1E and F) with con-
comitant downregulation of p-Rb were independent of p16
and p21 (Fig. 3A), we hypothesized that miR-433 may be
directly targeting a kinase involved in the cell cycle-depen-
dent phosphorylation of Rb. In this regard, it is known that
phosphorylation of Rb in the G1 phase of the cell cycle is
dependent on the activity of three complexes, namely, Cy-
clin D1/CDK4, Cyclin D1/CDK6, and Cyclin E/CDK2
(Fig. 4A) [30]. In our earlier bioinformatics analysis of
potential miR-433 targets, CDK6 was predicted by five of
the seven databases as a candidate miR-433 target gene.
Therefore, we set out to establish if miR-433 could regulate
the expression of CDK6. By analyzing protein expression in
both the miR-433 stable A2780 cells and the clonal deriva-
tive of this cell line, we observed a decrease in CDK6
expression (Fig. 4B and C, respectively). Additionally, tran-
sient overexpression of miR-433 in HeLa cells also demon-
strated downregulation of CDK6 (Fig. S1). Moreover, the
transient transfection of PEO1 cells with anti-miR-433 to
inhibit miR-433, resulted in a demonstrable upregulation
of CDK6 (Fig. 4D). Overall these data suggest that miR-
433-induced cellular senescence may be attributed to the
loss of CDK6. Ultimately, this would result in cells having a
reduced capacity to phosphorylate Rb, thereby, hindering
progression through the cell cycle.
High endogenous miR-433 expression
attenuates apoptosis allowing cells to
survive chemotherapy
The relationship between endogenous miR-433 expression
and chemoresistance to paclitaxel was investigated in the
A2780, PEO1, and PEO4 cell lines where we demon-
strated that chemosensitivity to paclitaxel correlated with
miR-433 expression levels. Specifically, A2780 which has
the lowest miR-433 expression (Fig. 3D) is the most
chemosensitive cell line in comparison to the more resis-
tant PEO1 and PEO4 cells which have higher endogenous
levels of miR-433 (Fig. 5A). We then determined if cells
that survive chemotherapy express increased levels of
miR-433. PEO1 and PEO4 cells were treated with paclit-
axel for 72 h after which fresh complete growth medium
was added and the cells were cultured for a further
8 days. qRT-PCR analysis of the cells surviving chemo-
therapy demonstrated a significant upregulation of miR-
433 expression in PEO1 by ~15-fold (P = 0.024) and in
PEO4 by ~12-fold (P = 0.0053) compared to untreated
cells (Fig. 5B). However,we did not observe statistical dif-
ference in the miR-433 expression after short 24 and 48 h
paclitaxel treatment (50 nmol/L) in both PEO1
(P = 0.155 and P = 0.55) and PEO4 cells (P = 0.24 and
P = 0.36) (Fig. S2). These data suggest that miR-433 is
not acutely upregulated by paclitaxel treatment. However,
significant upregulation of miR-433 8 days post paclitaxel
treatment suggests that only cells with the highest miR-
433 expression survive chemotherapy. Interestingly, PEO4
cells surviving paclitaxel treatment also demonstrated
senescence evidenced by increased b-galactosidase activity
(Fig. S2B). In the clinical setup, one could envisage that
these miR-433 enriched cells through environmental
selection over time, constitute chemoresistant clones
capable of seeding recurrent disease.
miR-433 expression impacts on cellular
senescence induction in the tumor
microenvironment
Senescent cells are known to directly impact on the tumor





Figure 4. miR-433 induces senescence by targeting CDK6. (A)
Schematic representation showing the published evidence of the
phosphorylation of Rb by three independent cyclin-dependent kinase
(CDK)/Cyclin complexes [30]. (B) Western blot analysis for CDK6
expression in the miR-433-stable line demonstrating downregulation
of CDK6. (C) Western blot analysis for CDK6 expression in the clonal
derivative miR-433-stable line demonstrating downregulation of
CDK6. (D) Western blot analysis for CDK6 reexpression in PEO1 cells
transfected with anti-miR-control and anti-miR-433 for 96 h
demonstrating an upregulation of CDK6.
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determine what effect GCM harvested from the miR-433-
stable transfected cells would have when used to culture
the parent A2780 cells. Results demonstrated that A2780
cells cultured in the GCM from miR-433 stable expressing
cells had a significantly increased growth inhibition
(MTT) compared to control cells (P = 0.012) (Fig. 6A).
Similarly, GCM from both PEO1 and PEO4 cells, which
display increased levels of miR-433, also influenced the
growth of control parent A2780 cells (Fig. 6B). Interest-
ingly, we observed a decrease in the expression levels of
p-Rb and the proliferation marker Ki67 in A2780 cells
incubated with GCM from PEO4 cells, the cisplatin-resis-
tant derivative of PEO1 and the cell line known to have
the highest levels of miR-433 (Fig. 6B).
It is well established that paracrine signaling between
senescent cells and the tumor microenvironment can
occur through the release of soluble factors such as cyto-
kines or through the release of microvesicles or exosomes
in various cancer cell lines including lung, prostate,
breast, and erythroleukaemic [32–35]. Therefore, we
investigated if miR-433 could be present in exosomes.
Exosomes were isolated from the miR-433-stable and
miR-control A2780 cells. Successful exosome isolation
was confirmed through nanoparticle tracking technology
(NanoSight) and the expression of miR-433 quantified
using qRT-PCR (Fig. S3A–C). From this we showed that
cells with stable expression of miR-433 also have
increased miR-433 levels in the exosomes which they
release (Fig. S3D). Simillarily, A2780, PEO1, and PEO4
exosomes were isolated from GCM and confirmed
through nanoparticle tracking technology (NanoSight)
(Fig. S3E–G) and the expression of miR-433 quantified
with qRT-PCR. Interestingly, we observed miR-433
expression in the exosomes derived from each cell line
(Fig. 6C).
To investigate if miR-433 could potentially be trans-
ported by vesicles, GCM from the A2780, PEO1, and
PEO4 cells were centrifuged to remove any dead cells
and cellular debris and subsequently labeled with the
lipophilic dye Dil. Using confocal microscopy, vesicle
uptake was observed in parent A2780 cells cultured in
the presence of labeled GCM from all three cell lines
(Fig. 6C). In summary, these data indicate that miR-
433-enriched cells have the ability to affect their tumor
microenvironment and to induce cellular senescence in
neighboring cells potentially by miR-433 incorporated
into vesicles.
Discussion
The contribution of altered miRNA expression to a
pathology such as cancer is now widely accepted. How-
ever, deciphering the exact function of a miRNA has pro-
ven more challenging. We present data demonstrating a
functional role of miR-433 in the induction of cellular
senescence, thereby conferring resistance to paclitaxel in
ovarian cancer cells. Our results indicated that miR-433
expression leads to functional inactivation of the Rb pro-
tein, followed by the disruption of cell cycle progression
and the induction of cellular senescence. The induction of
cellular senescence by miR-433 may initially act as a pro-
tective mechanism and thus arrest actively dividing cells
[8]. Indeed, in gastric cancer cells, miR-433 has been
attributed with tumor suppressor functions [20]. How-
ever, our data indicate that once a cancer cell has com-
mitted to a senescent phenotype, miR-433 can mediate
resistance to paclitaxel [5]. Of note is our finding that
cells surviving chemotherapy treatment are enriched in
miR-433. As paclitaxel treatment did not induce miR-433
expression, we suggest that miR-433 enrichment in post
A B
Figure 5. High miR-433 endogenous expression attenuates apoptosis with a resultant chemotherapy-induced senescence allowing cells to survive
chemotherapy. (A) MTT viability assay demonstrating the % of growth inhibition of the A2780, PEO1, and PEO4 cells treated with paclitaxel (10,
25, and 50 nmol/L) for 48 h, demonstrating an increased resistance to paclitaxel treatment in PEO1 and PEO4 cells. (B) qRT-PCR analysis of miR-
433 expression in PEO1 and PEO4 cells either untreated or treated with 50 nmol/L paclitaxel for 72 h, washed with PBS, and then cultured for
8 days in full growth medium showing an increased expression in cells treated with paclitaxel comparing to initial expression in untreated cells.
Error bars represent SEM. *P < 0.05, **P < 0.01.
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chemotherapy treated cell populations, is associated with
the survival of cells with the highest endogenous miR-433
and resultant senescent phenotype.
Clinically, cellular senescence-associated with the
expression of the p16/p-Rb pathway is widely present in




Figure 6. miR-433 expression has the potential to induce cellular senescence in the tumor microenvironment. (A) MTT viability assay
demonstrating a decreased viability in miR-control-stable cells treated with growth conditioned medium (GCM) from stable miR-433 expressing
cells compared to being cultured in control medium. (B) Western blot analysis of the expression of senescent markers of A2780 cells treated with
GCM from A2780, PEO1, or PEO4 cells demonstrating a marked reduction in p-RB and Ki67 when A2780 cells are grown in conditioned medium
from PEO4 cell line known to express the highest baseline levels of miR-433 (Fig. 3C). (C) Relative miR-433 expression in exosomes derived from
GCM harvested from A2780, PEO1, and PEO4 cells was assessed by TaqMan qRT-PCR using the comparative CT (DDCT) method. miR-433
expression was present in the exosomes derived from all cell lines. (D) Fluorescent micrograph showing a successful incorporation of Dil-labeled
vesicles from A2780, PEO1, or PEO4 GCM (shown in red) inside the recipient A2780 cells, counterstained with DAPI nuclear staining (shown in
blue) and microtubules with Alexa Fluor 488 a-tubulin staining (shown in green). Error bars represent SEM. *P < 0.05.
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estimates revealed a significant association between high
p16 expression and poor PFS [36]. The TCGA project has
also identified the Rb pathway as a major contributor to
HGSOC pathogenesis [37]. Recently, it has been shown
that functionally inactive Rb has a fundamental role in
promoting chromosome instability (CIN) [38]. CIN cou-
pled with its consequential chromosomal aneuploidy is a
main feature of advanced tumor grade and is strongly
associated with poor response to chemotherapies and fur-
ther tumor evolution [39]. Manning et al., have shown
that the induction of CIN is dependent on the synergistic
inactivation/mutation of both Rb and p53 [38]. Strik-
ingly, 95% of all ovarian tumors have p53 mutations
[37]. Therefore, miR-433-dependent functional silencing
of Rb (or in other words downregulation of p-Rb) in
p53-deregulated ovarian tumors could promote CIN and
contribute to further tumor development. Importantly,
our group has previously published that downregulation
of the miR-433 target, MAD2 and promoted anaphase
bridges formation which is a prerequisite to chromosomal
aneuploidy [21]. Consequently, the synergistic effect of
miR-433-dependent inactivation of Rb (possibly through
CDK6) and MAD2 may contribute to CIN in HGSOC.
Our bioinformatics analysis showed that miR-433 has
significant potential to regulate senescence-associated pro-
teins. Importantly, downregulation of four of these genes
namely: hPOT1, CREB1, Aurora A, and TOP1 has already
been shown to induce cellular senescence [40–43]. Downre-
gulation of others such as RAD21, TRIP12, E2F3, MED1,
SORBS2, HIPK2, SMC1A, and IQGAP1 has also been asso-
ciated with cell cycle inhibition. Importantly, in relation to
miR-433, two independent studies have demonstrated that
indeed, miR-433 expression is associated with migration
and invasion inhibition [17, 20]. Additionally, Guo et al.
associated miR-433 expression levels with a significant inhi-
bition of cell cycle progression in HGC-27 gastric cancer
cells [20]. In our study, for the first time we demonstrate
that stable miR-433 expression is also associated with the
induction of cellular senescence in A2780 ovarian cancer
cells. Furthermore, we show that senescence induction in
our model resulted from the downregulation of CDK6 in a
p21 and p16 independent manner. Senescence activation,
independent from canonical pathways (p53/p21 and p16/
Rb) has been reported previously [44, 45]. Specifically,
Rader et al. demonstrated that concomitant downregula-
tion of both CDK4/6 by either siRNA or the pharmacologi-
cal kinase inhibitor LEE011 caused cell cycle arrest,
followed by senescence in neuroblastoma [44]. Conversely,
Anders et al. have demonstrated that CDK4/6-dependent
activation of the FOXM1 transcription factor suppressed
senescence by an activation of critical G1/S genes promot-
ing S phase entry in melanoma cells [45]. Taking these data
together suggests that functional inactivation of CDK4/6 is
an important mechanism for cellular senescence induction
in various cancers.
Our data also indicate that miR-433 expressing cells
have the ability to affect their tumor microenvironment
by diminishing the proliferation in neighboring cells with
the induction of cellular senescence. The induction of cel-
lular senescence and subsequent altered cell signaling has
been shown to correlate with changes in the epigenome
of cells and to promote further cancer progression [46].
Yang and colleagues demonstrated that coinjection of
senescent ovarian fibroblasts with premalignant epithelial
cells into mice induced progression of senescence-depen-
dent carcinogenesis in vivo [47]. Additionally, senescent
cells secrete large amounts of signaling molecules, a fea-
ture known as the SASP [7]. In particular, IL6 and IL8
are known to correlate with poor survival and further
cancer development in patients presenting with EOC
[48]. Therefore, the induction of senescence by miR-433
may act to reinforce the cell’s response to uncontrollable
cell proliferation but ultimately the resultant senescent
phenotype may adversely affect the progression of the
cancer and patient survival.
In summary, this study has demonstrated how dysregu-
lation of a single microRNA, miR-433, through its regula-
tion of multiple protein targets results in the modulation
of cell signaling pathways to induce cellular senescence
and resistance to paclitaxel.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. (A) Western blot analysis of CDK6 expression
following transient transfection of pre-miR-433
(100 nmol/L) for 24 h in HeLa cells demonstrating the
downregulation of CDK6 in cells transfected with pre-
miR-433. (B) Fluorescent micrograph showing a success-
ful incorporation of a Cy3-labeled anti-miR-control
(shown in red) inside the cells with DAPI nuclear stain-
ing shown in blue. Cells were seeded into the four-well
chamber slides and transfected with 100 nmol/L of Cy3-
labeled anti-miR-control for 48 h. Subsequently the cells
were fixed counterstained with DAPI and visualized
using 405 nm excitation beam for DAPI and 559 nm for
Cy3.
Figure S2. (A) qRT-RCR analysis of miR-433 expression
in A2780, PEO1, and PEO4 cells treated with 50 nmol/L
paclitaxel for 24 and 48 h. (B) Senescence-dependent b-
galactosidase activity staining on the PEO1 and PEO4
cells treated with paclitaxel for 72 h and then recovered
in full growth medium for 8 days demonstrating and
increase in positively stained PEO4 cells.
Figure S3. miR-433 is present in exosomes harvested
from miR-433-stable GCM. (A) Size distribution of vesi-
cles isolated from miR-control and miR-433 stable cells
analyzed by Nanoparticle Tracking Technology—Nano-
Sight demonstrating the successful isolation of vesicles
ranging from 30 to 400 nm in both cell lines. (B) Graph
representing no significant difference between mean and
mode size distribution of the vesicles derived from GCM
of either miR-control and miR-433 stable cell quantified
by Nanoparticle Tracking Technology—NanoSight (C)
Quantification of exosomes derived from GCM of either
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miR-control or miR-433 stable cells calculated with
Nanoparticle Tracking Technology—NanoSight demon-
strating no significant difference in the amount of exo-
somes released per cells between these cell lines. (D)
Relative miR-433 expression in exosomes derived from
GCM harvested from miR-control or miR-433 stable cells
was assessed by TaqMan qRT-PCR using the compara-
tive CT (DDCT) method. Increased miR-433 expression
was observed in the A2780 stably expressing miR-433 cell
line compared to scrambled control. Increased miR-433
expression was only present in the miR-433 stable cells
and exosomes derived from these miR-433 stable cells.
(E) Size distribution of vesicles isolated from PEO1 and
PEO4 cells analyzed by Nanoparticle Tracking Technology
—NanoSight demonstrating the successful isolation of
vesicles ranging from 30 to 400 nm in both cell lines. (F)
Graph representing no significant difference between
mean and mode size distribution of the vesicles derived
from GCM of either PEO1 and PEO4 stable cell quanti-
fied by Nanoparticle Tracking Technology—NanoSight
(G) Quantification of exosomes derived from GCM of
either PEO1 or PEO4 cells calculated with Nanoparticle
Tracking Technology—NanoSight demonstrating no sig-
nificant difference in the amount of exosomes released
per cells between these cell lines. Error bars represent
SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
Table S1. Identification of candidate target genes of miR-
433 using seven different prediction databases. Genes pos-
itively identified by five of seven databases were used for
further analysis.
Table S2. KEGG pathway analysis of high confidence
miR-433 predicted target genes.
Table S3. List of genes which have previously been associ-
ated with cellular senescence.
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